XML 22 R11.htm IDEA: XBRL DOCUMENT
v3.21.2

Due To PAVmed Inc. | 9 Months Ended
--- | ---
Sep. 30, 2021
Debt Disclosure [Abstract] |
Due To PAVmed Inc. | Note 5 — Due To PAVmed Inc. The aggregate Due To: PAVmed Inc., inclusive of the Senior Unsecured Promissory Note, for the periods indicated is summarized as follows: Schedule of Senior Unsecured Promissory Note
|  | Note |  |  | Note |  |  | Advances |  |  | Payments |  |  | Fees |  |  | Total |
|  | Principal |  |  | Interest |  |  |  |  |  |  |  |  |  |  |  |  |
|  | Senior |  |  | Unsecured |  |  | Working |  |  | PAVmed |  |  |  |  |  |  |
|  | Unsecured |  |  | Senior |  |  | Capital |  |  | Inc. |  |  |  |  |  |  |
|  | Promissory |  |  | Promissory |  |  | Cash |  |  | OBO |  |  | MSA |  |  |  |
|  | Note |  |  | Note |  |  | Advances |  |  | Payments |  |  | Fees |  |  | Total |
Balance - December 31, 2020 |  | $ | — |  |  | $ | — |  |  | $ | 8,200,000 |  |  | $ | 2,361,435 |  |  | $ | 2,700,000 |  |  | $ | 13,261,435 |
Nine months ended September 30, 2021 |  |  | — |  |  |  | — |  |  |  | 7,738,910 |  |  |  | 178,309 |  |  |  | 2,510,000 |  |  |  | 10,427,219 |
Issue Unsecured Senior Promissory Note |  |  | 22,400,000 |  |  |  | — |  |  |  | (15,938,910 | ) |  |  | (2,411,090 | ) |  |  | (4,050,000 | ) |  |  | — |
Unsecured Senior Promissory Note - - Interest Expense |  |  | — |  |  |  | 593,813 |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 593,813 |
Balance - September 30, 2021 |  | $ | 22,400,000 |  |  | $ | 593,813 |  |  | $ | — |  |  | $ | 128,654 |  |  | $ | 1,160,000 |  |  | $ | 24,282,467 |
|  | Principal |  |  | Interest |  |  |  |  |  |  |  |  |  |  |  |  |
|  | Unsecured |  |  | Unsecured |  |  | Working |  |  | PAVmed |  |  |  |  |  |  |
|  | Senior |  |  | Senior |  |  | Capital |  |  | Inc. |  |  |  |  |  |  |
|  | Promissory |  |  | Promissory |  |  | Cash |  |  | OBO |  |  | MSA |  |  |  |
|  | Note |  |  | Note |  |  | Advances |  |  | Payments |  |  | Fees |  |  | Total |
Balance - December 31, 2019 |  | $ | — |  |  | $ | — |  |  | $ | 2,621,500 |  |  | $ | 1,678,927 |  |  | $ | 1,020,000 |  |  | $ | 5,320,427 |
Nine months ended September 30, 2020 |  |  | — |  |  |  | — |  |  |  | 3,978,500 |  |  |  | 334,425 |  |  |  | 1,110,000 |  |  |  | 5,422,925 |
Balance - September 30, 2020 |  | $ | — |  |  | $ | — |  |  | $ | 6,600,000 |  |  | $ | 2,013,352 |  |  | $ | 2,130,000 |  |  | $ | 10,743,352 |
Lucid Diagnostics Inc. has principally financed its operations through working capital cash advances from PAVmed Inc. and the periodic payment of certain operating expenses by PAVmed Inc. on-behalf-of Lucid Diagnostics Inc. (the “PAVmed Inc. OBO Payments”). Additionally, the daily operations of Lucid Diagnostics Inc. are managed by personnel employed by PAVmed Inc., for which the Company incurs expense according to the provisions of a Management Services Agreement (MSA) between the Company and PAVmed Inc (the “MSA Fee”). See Note 4, Related Party Transactions, for further information regarding the MSA. Senior Unsecured Promissory Note Subsequent to September 30, 2021, on October 13, 2021, Lucid Diagnostics Inc. issued 15,803,200 shares of its common stock to PAVmed Inc. upon the election by PAVmed Inc. to convert the $22.4 million face value principal under the terms of a Senior Unsecured Promissory Note, dated June 1, 2021. The Senior Unsecured Promissory Note was issued by Lucid Diagnostics Inc. to PAVmed Inc. with a face value principal of $22.4 million, which replaced the aggregate outstanding and payable balance of the Due To: PAVmed Inc. as of June 1, 2021, had an annual interest rate of 7.875%, a contractual maturity date of May 18, 2028, and, at the election of PAVmed Inc., provided for the partial or full repayment of the face value principal and accrued but unpaid interest thereon by the issue of shares of Lucid Diagnostics Inc. common stock at a conversion price of $1.42 per share of Lucid Diagnostics Inc. common stock.

X
- References No definition available. + Details
Name: | us-gaap_DebtDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -URI http://asc.fasb.org/topic&trid=2208564 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 20 -Section 50 -Paragraph 1B -Subparagraph (h) -URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 20 -Section 50 -Paragraph 1C -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 20 -Section 50 -Paragraph 1I -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 20 -Section 50 -Paragraph 1I -Subparagraph (d) -URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(c)) -URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 20 -Section 50 -Paragraph 1B -Subparagraph (g) -URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 20 -Section 50 -Paragraph 1C -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 20 -Section 50 -Paragraph 1C -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 20 -Section 50 -Paragraph 1E -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 20 -Section 50 -Paragraph 1B -URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 20 -Section 50 -Paragraph 1I -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 20 -Section 50 -Paragraph 1B -Subparagraph (i) -URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611 + Details
Name: | us-gaap_DebtDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration